IRF8 and neoplasm: cDC1s contribute to anti-tumor immunity via production of IL-12, as well as secretion of type I and III interferon (IFN) and expression of IRF8, but tumors may suppress IRF8 dependent development of cDC1s, limiting their antitumor effects [28].